Autoantibodies against the β3-adrenoceptor protect from cardiac dysfunction in a rat model of pressure overload

Jin Wang1, Meixia Li, Xiurui Ma

  • 1Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi, P. R. China.

Plos One
|October 23, 2013
PubMed

Insights

Autoantibodies against beta-3 adrenoceptors (β3-AR Abs) are elevated in heart failure (HF) patients. These β3-AR Abs protect against pressure overload, improving cardiac function and reducing cardiomyocyte calcium transients.

Area of Science:

  • Cardiology
  • Immunology
  • Molecular Biology

Background:

  • Beta-3 adrenoceptors (β3-ARs) have a negative inotropic effect in cardiomyocytes, contrasting with β1- and β2-ARs.
  • Autoantibodies against β1/β2-ARs are found in heart failure (HF) patients and exhibit agonist-like effects.

Purpose of the Study:

  • To determine the presence of β3-AR autoantibodies (β3-AR Abs) in HF patients.
  • To evaluate the impact of β3-AR Abs on a rat model of pressure overload cardiomyopathy.

Main Methods:

  • ELISA screening of β3-AR Abs in HF patient sera.
  • Administration of β3-AR Abs to rats with abdominal aortic banding (AAB) to assess cardiac function via echocardiography and hemodynamics.
  • Evaluation of β3-AR Ab effects on cardiomyocyte contractility, intracellular calcium transients, and L-type calcium currents.

Main Results:

  • HF patients showed significantly increased frequency and titers of β3-AR Abs compared to healthy individuals.
  • Administration of β3-AR Abs prevented left ventricular dilation and improved cardiac function in AAB rats.
  • β3-AR Abs induced negative chronotropic and inotropic effects, associated with reduced intracellular Ca(2+) transients and L-type Ca(2+) currents in cardiomyocytes.

Conclusions:

  • β3-AR Abs exist in HF patients and can alleviate cardiac dysfunction caused by pressure overload.
  • These findings suggest a protective role for β3-AR Abs in pressure-induced heart dysfunction.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
3.0K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K